Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CTSS siRNA is a small interfering RNA designed to silence the expression of Cathepsin S (CTSS), a lysosomal cysteine protease. In the context of head and neck cancer research, CTSS has been identified as a negative regulator of interleukin 7 (IL-7) secretion. By knocking down CTSS, the siRNA promotes the expression of the IL-7 receptor and subsequent IL-7 secretion, which enhances the proliferation and infiltration of activated CD8+ T cells within the tumor microenvironment. This approach aims to reverse the immune-suppressed state associated with high CTSS expression in cancers and is currently being explored in preclinical models.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CTSS siRNA.